Table 2.
Vital signs and clinical variables at the time of PET1 and PET2
| Variable | PET1 | PET2 | p valuea |
|---|---|---|---|
| Physiologic measurements, mean ± SD | |||
| Heart rate (bpm) | 70 ± 12 | 68 ± 11 | 0.30 |
| Blood pressure (mmHg) | |||
| Systolic | 127 ± 21 | 130 ± 21 | 0.38 |
| Diastolic | 73 ± 14 | 76 ± 21 | 0.38 |
| Rate–pressure product | 8,846 ± 2,100 | 8,832 ± 1,935 | 0.96 |
| Myocardial blood flow (cm3/min/g), median (interquartile range) | |||
| Resting | 0.85 (0.65–1.08) | 0.88 (0.67–1.07) | 0.49 |
| Stress | 1.26 (1.03–1.39) | 1.35 (1.04–1.7) | 0.002 |
| Coronary flow reserve | 1.38 (1.2–1.7) | 1.60 (1.36–1.82) | 0.005 |
| Abnormality (percentage of myocardium), median (interquartile range) | |||
| Perfusion abnormality | 14 (6–21) | 2 (0–6) | <0.001 |
| Severe coronary flow capacity reduction | 33 (13–47) | 12 (1–38) | <0.001 |
| Tobacco use, n (%) | 11 (22) | 4 (8) | 0.09 |
| Medication, n (%) | |||
| Beta-blocker | 41 (82) | 44 (88) | 0.58 |
| ACE inhibitor/ARB | 41 (82) | 41 (82) | 1.0 |
| Statin | 40 (80) | 48 (96) | 0.03 |
| Calcium channel blocker | 18 (36) | 20 (40) | 0.84 |
| Aspirin | 43 (86) | 48 (96) | 0.16 |
| Platelet Inhibitor | 36 (62) | 45 (90) | 0.04 |
| Nitrate | 13 (26) | 12 (24) | 1.0 |
| Diuretic | 20 (40) | 22 (44) | 0.84 |
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker
aValues <0.05 are indicated in bold type